NASDAQ:CHRS - Coherus BioSciences, Inc.
$14.71
 $-0.03
-0.20%
4:00PM EDT
2019-04-18
Coherus BioSciences, Inc. is a late-stage clinical biologics platform company. The Company is engaged in the business of developing and commercializing biosimilar products. The Company's business is organized around therapeutic franchises, including Oncology biosimilar candidates pegfilgrastim (Neulasta) and bevacizumab (Avastin); Immunology (Anti-TNF) biosimilar candidates etanercept (Enbrel) and adalimumab (Humira); Ophthalmology biosimilar candidate ranibizumab (Lucentis), and Multiple sclerosis small molecule therapeutic candidate, CHS-131. The Company's product candidate pipeline includes CHS-1701, CHS-5217, CHS-0214, CHS-1420 and CHS-3351. Its CHS-1701 is a Granulocyte colony-stimulating factor (G-CSF) product candidate. Its Bevacizumab is a recombinant humanized monoclonal antibody that blocks angiogenesis by inhibiting vascular endothelial growth factor A (VEGF-A). Its Etanercept (Enbrel) is the reference product for CHS-0214. Read more at  reuters.com
sector:  health care
industry:  biotechnology
the data below are updated and published after 9pm EDT each trading day
  CHRS     avg for
industry  
  avg for
sector  
42 stocks weight:  17. 67   199. 07   233. 87  
42 stocks rank:  2. 83 K 1. 43 K 1. 06 K
# analyst opinions:  4. 00   14. 48   14. 09  
mean recommendation:  1. 60   2. 09   2. 01  

quick ratio:  2. 17   5. 29   1. 92  
current ratio:  2. 54   5. 64   2. 40  

target price low:  25. 00   84. 50   115. 74  
target price avg:  29. 00   110. 73   137. 39  
target price high:  35. 00   136. 41   157. 80  
1-yr high:  20. 25   114. 11   138. 85  
last close:  14. 71   87. 56   116. 78  
50-day avg:  14. 37   95. 43   123. 53  
200-day avg:  14. 24   94. 13   121. 20  
1-yr low:  8. 38   72. 67   98. 41  
volume:  884. 43 K 2. 43 M 4. 85 M
50-day avg volume:  798. 41 K 2. 72 M 4. 97 M
200-day avg volume:  709. 19 K 2. 90 M 4. 58 M

1-day return:  -0. 20 % -0. 40 % 0. 07 %
this week return:  -0. 47 % -5. 72 % -4. 11 %
12-wk return:  20. 38 % 1. 78 % -0. 04 %
52-wk return:  17. 57 % 10. 81 % 14. 09 %

enterprise value (EV):  1. 05 B 51. 19 B 117. 96 B
market cap:  1. 02 B 43. 00 B 104. 52 B
EBITDA:  -197. 32 M 4. 45 B 8. 01 B
enterprise multiple (EV/EBITDA):  -5. 34   4. 34   13. 27  
total debt:  103. 09 M 12. 22 B 16. 66 B
net income (common):  -209. 34 M 2. 20 B 4. 21 B

shares outstanding:  69. 26 M 570. 91 M 1. 24 B
shares:  58. 59 M 571. 02 M 1. 23 B
shares short:  8. 86 M 9. 93 M 16. 79 M
shares short prior month:  9. 12 M 9. 96 M 16. 58 M
short ratio:  10. 97   5. 31   3. 30  
short % of float:  24. 36 % 5. 81 % 2. 61 %
total cash/share:  1. 04   11. 13   9. 30  
total cash:  72. 36 M 6. 70 B 7. 10 B
free cash flow:  -81. 32 M 3. 58 B 4. 74 B
operating cash flow:  -159. 27 M 4. 14 B 6. 32 B

book value:  -0. 56   12. 76   26. 84  
price/book:  -26. 04   3. 08   -1. 74  
gross profits:  -106. 38 M 8. 03 B 34. 77 B
operating margins:  0. 00 % -721. 97 % -88. 82 %
EBITDA margins:  0. 00 % 10. 94 % 22. 54 %
profit margins:  0. 00 % 7. 81 % 10. 60 %
gross margins:  0. 00 % 37. 02 % 55. 68 %

1-yr max volatility:  20. 13 % --- ---
1-yr mean volatility:  0. 15 % 0. 03 % 0. 04 %

1-yr EPS:  -3. 22   2. 39   4. 08  
forward EPS:  -0. 12   3. 97   7. 14  
P/E:  -4. 57   13. 59   22. 83  
forward P/E:  -123. 17   -20. 05   14. 49  
PE/G:  0. 29   -1. 46   1. 68  
growth:  -15. 62 % 126. 81 % 29. 29 %
earnings high:  -0. 38   1. 02   1. 63  
earnings avg:  -0. 46   0. 76   1. 51  
earnings low:  -0. 52   0. 47   1. 39  
revenue high:  37. 43 M 2. 68 B 10. 71 B
revenue avg:  37. 05 M 2. 59 B 10. 49 B
revenue low:  36. 79 M 2. 49 B 10. 25 B
return on assets:  -95. 66 % -2. 80 % 5. 29 %

beta (1yr vs S&P500):  1. 47   1. 24   0. 93  
sharpe (1yr):  0. 56   0. 29   0. 60  

held % insiders:  3. 54 % 6. 38 % 3. 38 %
held % institutions:  97. 45 % 78. 60 % 68. 65 %

Research more with google or yahoo!
the data below are updated and published after 9pm EDT each trading day

2019-04-19 : CHRS
.    + 0.616 =         0.616 :: INITIAL WEIGHT
.   + 62.586 =        63.202 :: inverse volume-to-price addition
.   + 43.899 =       107.102 :: spline projection addition
.    x 7.057 =       755.801 :: 13 weeks' performance factor
.    x 1.132 =       855.218 :: one-year gains+dividend factor
.    x 1.432 =      1224.692 :: industry recommendation factor
.    x 2.542 =      3112.669 :: symbol recommendation factor
.     x 0.99 =      3082.894 :: return on assets factor
.     x 2.45 =      7553.464 :: current ratio factor
.    x 1.361 =     10276.776 :: quick ratio factor
.    x 1.045 =     10734.965 :: short ratio factor
.     x 1.74 =      18675.04 :: price-to-book factor
.    x 1.042 =     19465.164 :: 5-day avg > 200-day avg
.    x 1.033 =     20103.579 :: 5-day avg > 50-day avg
.    x 1.009 =     20288.718 :: 50-day avg > 200-day avg
.    x 2.095 =     42513.871 :: P/E weight
.     x 1.36 =      57807.17 :: PE/G factor
.    x 1.494 =     86368.328 :: beta factor
.    x 0.564 =     48741.652 :: sharpe factor
.    x 1.915 =     93341.327 :: target low factor
.    x 1.329 =    124007.705 :: target mean factor
.    x 1.117 =    138571.795 :: target high factor
.    x 1.312 =    181757.472 :: industry 2-weeks return factor
.    x 0.999 =    181498.086 :: overall "drift" factor
.    x 0.799 =    144954.846 :: largest single-day jump factor
.    x 0.405 =     58686.173 :: low price factor
.      x 1.0 =     58676.713 :: factor hist industry gain for week 15
.   cubeRoot =        38.859 :: reduced to standardize
.   - 21.191 =        17.668 :: add/subtract for performance
.                     17.668 :: FINAL WEIGHT for NASDAQ:CHRS


 


News feed RSS items generated from finance.google.com

News feed formatting by feed2js.org